TGTXTG Therapeutics, Inc.

908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago. Speaking at a Canaccord Genuity event, President, CEO and Co-Founder K

BRIUMVI revenue surged 64% year-over-year as patient starts hit record levels.

TG Therapeutics (TGTX) drew fresh attention after reporting second quarter 2026 results, with revenue of US$240.34 million and earnings of US$0.05 per share, alongside higher full-year revenue guidance near US$950 million. See our latest analysis for TG Therapeutics. Despite raising guidance and reporting strong revenue growth for BRIUMVI, TG Therapeutics has seen its recent momentum cool, with the share price down 11.26% over 1 day and 15.86% over 7 days. However, the year-to-date share...

Moby summary of TG Therapeutics, Inc.'s Q2 2026 earnings call

TG Therapeutics stock has delivered a very large 3 year return, yet the valuation checks still suggest the shares lean cheap overall, even after recent short term declines. Over the past 3 years, TG Therapeutics has returned about 3.8x, which puts the recent pullback in the context of a much longer run up for existing shareholders. Expectations around continued uptake of BRIUMVI can support optimism on future revenue, while higher spending and earnings falling short of some expectations may...

TG Therapeutics reported past Q2 2026 results showing revenue rising to US$240.34 million from US$141.15 million a year earlier, while net income declined to US$7.78 million and EPS came in at US$0.05, missing consensus estimates. The company also raised its 2026 global revenue outlook to about US$950 million, underscoring confidence in Briumvi’s momentum and its broader pipeline progress across multiple immune-mediated diseases. We’ll now examine how the raised full-year revenue guidance...

Top-notch biotech stocks TG Therapeutics and Twist Bioscience diverged Monday on mixed earnings reports.

TG Therapeutics misses Q2 earnings estimates, but surging Briumvi demand lifts revenues y/y and prompts higher 2026 revenue guidance. Stock falls.

TG Therapeutics (NASDAQ:TGTX) reported second-quarter 2026 revenue of $240 million and raised its full-year sales outlook for BRIUMVI, its treatment for relapsing multiple sclerosis, as the company cited record new patient starts, continued prescriber expansion and higher-than-expected treatment per

The headline numbers for TG Therapeutics (TGTX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

The biotech firm increased its 2026 total global revenue target to around $950 million, up from $925 million previously.

TG Therapeutics, Inc. (NASDAQ:TGTX) increased its full-year 2026 revenue guidance after reporting another quarter of strong sales growth for its multiple sclerosis treatment, Briumvi, according to the company’s latest earnings release.

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -87.81% and +4.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics is Friday's IBD Stock Of The Day after shares rebounded into a profit-taking zone on key comments from chief rival Roche.

ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “SMID Cap Growth Strategy”. A copy can be downloaded here. Small and mid-cap (SMID) growth equities experienced the strongest quarter in recent memory, with the Russell 2500 Growth Index rising 24.0%, driven by enthusiasm for AI infrastructure and higher-beta momentum stocks. The […]